Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in primary warm autoimmune hemolytic anemia (PATHWAY)
NL-OMON52364Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of parsaclisib in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Incyte. Primary endpoint: Durable hemoglobin response. Planned start Nov 2021; status: withdrawn.
02
Drugs
parsaclisib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON52364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52364.